KAS
VRNA

Kestra Advisory Services’s Verona Pharma VRNA Stock Holding History

Kestra Advisory Services’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,955
Closed -$563K – 3035
2025
Q2 		$563K Buy
5,955
+2,172
+57% +$161K ﹤0.01% 1879
2025
Q1 		$240K Buy
+3,783
New +$226K ﹤0.01% 2341
2024
Q4 		– Sell
-8,158
Closed -$235K – 2825
2024
Q3 		$235K Buy
+8,158
New +$201K ﹤0.01% 2259

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kestra Advisory Services's VRNA Position: Q3 2025 in Review

Kestra Advisory Services sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 5,955 shares — an estimated $563K sold.

Kestra Advisory Services first reported a position in VRNA in Q3 2024 and held it in 3 quarters. The position peaked at $563K in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Kestra Advisory Services reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Kestra Advisory Services sold 5,955 Verona Pharma shares in Q3 2025, an estimated $563K.
  • Kestra Advisory Services first reported a position in Verona Pharma in Q3 2024 and held it in 3 quarters.
  • Kestra Advisory Services's Verona Pharma position peaked at $563K in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Kestra Advisory Services's 13F filing for Q3 2025, filed 14 Nov 2025.